Skip header and navigation

Refine By

3 records – page 1 of 1.

Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.

https://arctichealth.org/en/permalink/ahliterature123703
Source
Acta Oncol. 2012 Nov;51(8):1036-44
Publication Type
Article
Date
Nov-2012
Author
Kenneth Geving Andersen
Maj-Britt Jensen
Henrik Kehlet
Rune Gärtner
Lise Eckhoff
Niels Kroman
Author Affiliation
Section for Surgical Pathophysiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark. kenneth.geving.andersen@rh.regionh.dk
Source
Acta Oncol. 2012 Nov;51(8):1036-44
Date
Nov-2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage - adverse effects
Breast Neoplasms - drug therapy - radiotherapy - surgery
Chemotherapy, Adjuvant
Cross-Sectional Studies
Cyclophosphamide - administration & dosage - adverse effects
Denmark - epidemiology
Epirubicin - administration & dosage - adverse effects
Female
Fluorouracil - administration & dosage - adverse effects
Foot - physiopathology
Hand - physiopathology
Humans
Lymph Node Excision
Mastectomy - methods
Middle Aged
Multivariate Analysis
Neuralgia - chemically induced - epidemiology
Pain Measurement
Prevalence
Prospective Studies
Questionnaires
Radiotherapy - adverse effects
Risk factors
Sensation Disorders - chemically induced - epidemiology
Severity of Illness Index
Taxoids - administration & dosage - adverse effects
Abstract
Taxanes used in adjuvant therapy for breast cancer are neurotoxic, and thereby being a potential risk factor for persistent pain after breast cancer treatment (PPBCT) and sensory disturbances. The purpose was to compare patients treated with cyclophosphamide, epirubicin and fluorouracil (CEF) and cyclophosphamide and epirubicin + docetaxel (CE + T) in relation to PPBCT, sensory disturbances, peripheral sensory disturbances and functional impairment.
A comparative nationwide cross-sectional questionnaire study on two cohorts treated with CEF respectively CE + T, based on the Danish Breast Cancer Cooperative Groups database.
women treated with chemotherapy as adjuvant treatment for primary breast cancer, age 18-69 years, without recurrence.
One thousand two hundred and forty-one patients allocated to CEF in 2005-2006 and 1652 patients allocated to CE + T in 2007-2008 were included. Six hundred and sixty-four (53%) with CEF and 861 (53%) patients with CE + T reported pain. In the multivariate analysis including available risk factors, CE + T did not confer an increased risk of PPBCT, OR 0.95 (95% CI 0.81-1.11), p =?0.52, compared to CEF. Patients treated with CE + T had a lower risk of sensory disturbances in the area of surgery compared with CEF, OR 0.75 (95% CI 0.62-0.90), p =?0.002. More CE + T patients reported peripheral sensory disturbances in the hands, OR 1.56 (95%CI 1.27-1.92), p
PubMed ID
22676048 View in PubMed
Less detail

TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.

https://arctichealth.org/en/permalink/ahliterature101282
Source
Acta Oncol. 2011 Aug 9;
Publication Type
Article
Date
Aug-9-2011
Author
Lise Eckhoff
Mette Nielsen
Susanne Moeller
Ann Knoop
Author Affiliation
Department of Oncology, Odense University Hospital , Odense , Denmark.
Source
Acta Oncol. 2011 Aug 9;
Date
Aug-9-2011
Language
English
Publication Type
Article
Abstract
Abstract Background. In 2007 docetaxel was introduced as part of the adjuvant setting offered to high risk breast cancer patients in Denmark. Meta-analyses had shown that taxane-containing chemotherapy reduced the relative risk of relapse and death by 20-30%, apparently with moderate side effects. The treatment was given as three cycles of cyclophosphamide (600 mg/m(2)) and epirubicin (90 mg/m(2)) followed by three cycles of docetaxel (100 mg/m(2)). Because of an apparent high incidence of side effects, especially febrile neutropenia (FN) and non-hematologic side effects, the DBCG (The Danish Breast Cancer Cooperative Group) initiated a retrospective study of adverse reactions to the newly introduced regime and all patients were offered primary prophylaxis with growth factors (G-CSF) pr 1/1-2008. Material and methods. Two medical doctors examined available journals and nurse charts from the 13 oncology departments in Denmark, and graded all side effects according to NCI CTC version 2.0. To be enrolled, the patients should have received three cycles of EC and at least one cycle of docetaxel. The side effects were investigated before and after routine use of G-CSF. Results. One thousand one hundred and forty-three patients entered the study. In 2007 (before G-CSF) the incidence of FN was 25% and 90.6% of the patients completed the planned treatment. In 2008 (after the introduction of G-CSF) the incidence of FN was 10% and 94.5% completed the treatment. The incidence of non-hematological adverse events, in 2007 and 2008 combined, was for neuropathy 35%, mucositis 75%, muscle and joint pain 53%, skin rash 25% and fatigue 43% (all grades). Conclusion. The introduction of G-CSF was justified because of the high incidence of FN. However, it could not have been predicted after reviewing the published literature. The incidence of non-hematological adverse events had been reported in some, but not all adjuvant taxanes studies. In the future, focus should be more on the side effects, especially when introducing new toxic systemic regimes.
PubMed ID
21824038 View in PubMed
Less detail